Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow CalciMedica, Inc.

Get SEC filing alerts via email and in your feed for CalciMedica, Inc.

CALC

CalciMedica, Inc.

About CalciMedica, Inc.

CalciMedica is a clinical-stage biopharmaceutical company developing innovative therapeutics targeting calcium release-activated calcium (CRAC) channels. Its lead product, Auxora, is a selective IV CRAC channel inhibitor aimed at treating acute critical illnesses such as pancreatitis, kidney injury, and respiratory failure. The company's dual anti-inflammatory and tissue-protective approach addresses unmet needs in severe inflammatory and immunologic diseases across acute and chronic markets.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from CalciMedica, Inc.

1
1
CalciMedica, Inc. CalciMedica Reports $4.976 Million Net Income in Q1 2026, Significant Turnaround from Previous Year

Via official filing (AI summary) | 23 days ago | 0 comments

2
1
CalciMedica, Inc. CalciMedica Reports $29.6 Million Net Loss for 2025, Discontinues KOURAGE Trial

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
CalciMedica, Inc. CalciMedica Reports $7.8 Million Net Loss in Q3 2025, Seeks Funding for Clinical Programs

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
CalciMedica, Inc. CalciMedica Reports Increased Net Loss of $10.998 Million for First Half of 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
CalciMedica, Inc. CalciMedica Reports $5 Million Net Loss in Q1 2025 Amid Increased R&D Expenses

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
CalciMedica, Inc. CalciMedica Reports $13.7 Million Net Loss for 2024, Improved from $34.36 Million in 2023

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
CalciMedica, Inc. CalciMedica Reports Financial Update, Advances Lead Product Candidate Auxora

Via official filing (AI summary) | over 1 year ago | 0 comments